Two-Year Follow-Up of a Patient With Successful Continuation of Clozapine Treatment Despite Morning Pseudoneutropenia
J Clin Psychiatry 2004;65(9):1281[letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: Agranulocytosis occurs in 1% to 2% of patients treated with clozapine. Thus, if neutropenia (absolute neutrophil count [ANC] of < 1500/µL) occurs during clozapine treatment, physicians generally interrupt the drug treatment and do not reintroduce it. Lithium and granulocyte colony-stimulating factor may be used to reverse clozapine-induced granulocytopenia.1 We have previously reported the case of a patient who was able to continue clozapine treatment despite developing “morning pseudoneutropenia” (MPN).2